|
- Drugs - World Health Organization (WHO)
The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important
- 基本药物 - World Health Organization (WHO)
基本药物是有效安全地满足人民医疗保健需求的药物。世卫组织根据公共卫生相关性、有关益处和危害的证据并考虑成本、负担能力和其他相关因素来选择基本药物。
- Alcohol, Drugs and Addictive Behaviours
Alcohol, Drugs and Addictive Behaviours The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours
- Drugs (psychoactive) - World Health Organization (WHO)
Substitution maintenance therapy with methadone or buprenorphine improves the health and social performance of opioid-dependent people and decreases the use of illicit drugs and the crime rate Statistics show that investment in prevention pays off well: every dollar invested in drug treatment saves seven dollars in health and social costs
- WHO announces landmark changes in treatment of drug-resistant tuberculosis
The World Health Organization (WHO) today released its Consolidated guidelines on tuberculosis (TB)- Module 4: treatment and care, consolidating all previous guidelines into a single comprehensive document and introducing significant improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR RR-TB)
- Guidelines for HIV post-exposure prophylaxis
WHO’s updated PEP guidelines prioritize broader access to PEP, including community-based delivery and task sharing to mitigate barriers such as stigma and to ensure timely access post exposure PEP involves administering antiretroviral (ARV) medication after potential HIV exposure to prevent infection
- Antifungal agents in clinical and preclinical development: overview and . . .
This report presents the first World Health Organization (WHO) analysis of antifungal agents in preclinical and clinical development It covers systemic antifungal drugs in development worldwide, including label extension and repurposed products, and critically evaluates how well the current pipeline addresses infections caused by WHO fungal priority pathogens
- UN Commission approves WHO recommendations to place psychoactive . . .
Following recommendations by the World Health Organization (WHO), the United Nations Commission on Narcotic Drugs (CND) has decided to place five new psychoactive substances and one medicine under international control
|
|
|